Fibrosis

Veracyte Announces Data Published in The Lancet Respiratory Medicine Demonstrate that the Envisia Genomic Classifier Improves Diagnosis of IPF

Retrieved on: 
Monday, April 1, 2019
Health, Biotechnology, Clinical trials, Medical devices, Oncology, Pharmaceutical, Research, Science, Medicine, RTT, Health, Respiratory system, Idiopathic pulmonary fibrosis, Interstitial lung disease, IPF, Pulmonary fibrosis, Respiratory disease, Fibrosis, Pneumonia, Idiopathic interstitial pneumonia

announced that data published online today in The Lancet Respiratory Medicine suggest that use of the companys Envisia Genomic Classifier improves diagnosis for patients undergoing evaluation for interstitial lung diseases (ILDs), including idiopathic pulmonary fibrosis (IPF).

Key Points: 
  • announced that data published online today in The Lancet Respiratory Medicine suggest that use of the companys Envisia Genomic Classifier improves diagnosis for patients undergoing evaluation for interstitial lung diseases (ILDs), including idiopathic pulmonary fibrosis (IPF).
  • The Envisia classifier is the first commercially available test that may help distinguish IPF from other ILDs, without the need for risky surgery.
  • The Envisia Genomic Classifier is the first commercially available test to improve the diagnosis of idiopathic pulmonary fibrosis (IPF).
  • Veracyte, Afirma, Percepta, Envisia and the Veracyte logo are trademarks of Veracyte, Inc.
    View source version on businesswire.com: https://www.businesswire.com/news/home/20190401005944/en/

Pliant Therapeutics Presents Data in Human NASH Liver Tissue at The International Liver Congress 2019 Hosted by the European Association for the Study of the Liver (EASL)

Retrieved on: 
Thursday, March 28, 2019
Medical specialties, Medicine, Clinical medicine, Hepatitis, RTT, Non-alcoholic fatty liver disease, Steatohepatitis, Cirrhosis, Alcoholic liver disease, Fibrosis

The company's PLN-1474 program is targeting late-stage liver fibrosis (i.e., F3/F4) associated with nonalcoholic steatohepatitis (NASH).

Key Points: 
  • The company's PLN-1474 program is targeting late-stage liver fibrosis (i.e., F3/F4) associated with nonalcoholic steatohepatitis (NASH).
  • "Up to now, only modest improvements in liver fibrosis stage or severity have been reported with investigational compounds evaluated in patients with nonalcoholic steatohepatitis.
  • In further in vivo studies, inhibition of v1 was evaluated in a model of precision cut liver slices from CCl4-treated mice and explanted human cirrhotic liver tissue.
  • Pliant Therapeutics is a clinical stage biotechnology company targeting the key biological pathways driving fibrosis.

Global Idiopathic Pulmonary Fibrosis Partnering Deals and Agreements Directory 2019

Retrieved on: 
Wednesday, March 20, 2019
Medicine, Medical terminology, Health, Branches of biology, Idiopathic pulmonary fibrosis, RTT, Idiopathic disease, Pulmonary fibrosis, Fibrosis

The "Global Idiopathic Pulmonary Fibrosis Partnering 2014 to 2019" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Idiopathic Pulmonary Fibrosis Partnering 2014 to 2019" report has been added to ResearchAndMarkets.com's offering.
  • The Global Idiopathic Pulmonary Fibrosis Partnering Terms and Agreements since 2014 report provides understanding and access to partnering deals and agreements entered into by the world's leading healthcare companies.
  • Chapter 3 provides a comprehensive directory of partnering deals signed and announced since 2014.
  • Global Idiopathic Pulmonary Fibrosis Partnering Terms and Agreements since 2014 report provides the reader with the following key benefits:
    Insight into key deal terms included in contracts, where disclosed
    Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Boehringer Ingelheim announces FDA and EMA regulatory submission for nintedanib in systemic sclerosis associated ILD

Retrieved on: 
Monday, March 18, 2019
Health, Clinical trials, Pharmaceutical, Research, FDA, Science, Health, Medicine, Clinical medicine, Interstitial lung disease, Breakthrough therapy, Idiopathic pulmonary fibrosis, Nintedanib, Boehringer Ingelheim, Pulmonary fibrosis, Fibrosis

Boehringer Ingelheim has filed for regulatory approval of nintedanib in patients with systemic sclerosis associated interstitial lung disease (SSc-ILD) with the FDA and EMA.

Key Points: 
  • Boehringer Ingelheim has filed for regulatory approval of nintedanib in patients with systemic sclerosis associated interstitial lung disease (SSc-ILD) with the FDA and EMA.
  • Nintedanib as an anti-fibrotic medicine is already approved in more than 70 countries for the treatment of patients living with idiopathic pulmonary fibrosis (IPF).
  • Pulmonary fibrosis is a key driver of mortality in systemic sclerosis, and currently there are no approved treatments for SSc-ILD.
  • Boehringer Ingelheim is pleased that we are able to take a step closer to potentially bringing an approved treatment for addressing the decline in lung function to patients with this rare condition.

Broadway Stars Set Fundraising Record To Fight Lung Disease

Retrieved on: 
Thursday, March 14, 2019
Medicine, Pulmonary fibrosis, Fibrosis, Health, Clinical medicine, RTT, Occupational diseases, Hypertension, Usual interstitial pneumonia

The star-studded gala supportsprograms and research to advance a cure for pulmonary fibrosis, a life-threatening disease which causes progressive scarring in the lungs.

Key Points: 
  • The star-studded gala supportsprograms and research to advance a cure for pulmonary fibrosis, a life-threatening disease which causes progressive scarring in the lungs.
  • More than 200,000 Americans are living with pulmonary fibrosis and 50,000 new cases are diagnosed each year.
  • "The tireless work of the Pulmonary Fibrosis Foundation is leading the way toward a cure for this terrible disease."
  • "Thanks to Julie Halston, the cast and crew of Broadway Belts, we are getting closer to a world without pulmonary fibrosis."

Global Idiopathic Pulmonary Fibrosis Treatment Market Outlook by Treatment Type, Gender, Age Group and Geography (2019-2024) - ResearchAndMarkets.com

Retrieved on: 
Thursday, March 7, 2019
Health, Pharmaceutical, Medicine, Medical terminology, Health, Branches of biology, Pulmonary fibrosis, Fibrosis, Idiopathic disease, Idiopathic pulmonary fibrosis, Monoclonal antibodies

The "Idiopathic Pulmonary Fibrosis Treatment Market - Forecasts from 2019 to 2024" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Idiopathic Pulmonary Fibrosis Treatment Market - Forecasts from 2019 to 2024" report has been added to ResearchAndMarkets.com's offering.
  • The global idiopathic pulmonary fibrosis treatment market is expected to reach US$4.02 billion by 2024 from US$2.09 billion in 2018, at a CAGR of 11.52%.
  • The values obtained are correlated with the primary inputs of the key stakeholders in the global idiopathic pulmonary fibrosis market value chain.
  • Market intelligence is presented in the form of analysis, charts, and graphics to help the clients in gaining faster and efficient understanding of the global idiopathic pulmonary fibrosis market.

Forbius Announces the First Patient Dosed in a Phase 1b Diffuse Cutaneous Systemic Sclerosis Trial of AVID200, a Novel TGF-beta 1 & 3 Inhibitor

Retrieved on: 
Tuesday, March 5, 2019
Health, Biotechnology, Clinical trials, Oncology, Pharmaceutical, Branches of biology, Medicine, Proteins, Transforming growth factor beta, Clinical medicine, TGF beta 1, Fibrosis, Scleroderma, TGF beta Activation

, Professor of Medicine, Medsger Professor and Director of the Scleroderma Center at the University of Pittsburgh Medical Center.

Key Points: 
  • , Professor of Medicine, Medsger Professor and Director of the Scleroderma Center at the University of Pittsburgh Medical Center.
  • AVID200 selectively neutralizes TGF-beta 1 & 3 with best-in-class pM potency, thus simultaneously neutralizing the principal pro-fibrotic TGF-beta isoforms and providing optimal efficacy.
  • For decades, safe and potent neutralization of TGF-beta has been the holy grail for the treatment of fibrotic diseases.
  • AVID200 is a rationally designed, highly potent TGF-beta 1 & 3 inhibitor undergoing Phase 1 clinical testing in fibrosis and solid tumors.

A cure is in the cards: Play a royal flush and win in the fight against pulmonary fibrosis

Retrieved on: 
Wednesday, February 27, 2019
Medicine, Pulmonary fibrosis, Fibrosis, Respiratory disease

In honor of Irv, the family hosts poker and casino night to raise money to help end pulmonary fibrosis.

Key Points: 
  • In honor of Irv, the family hosts poker and casino night to raise money to help end pulmonary fibrosis.
  • Playing poker is a passionate Feldman family pastime and one of the few times Irv Feldman could forget his fight against pulmonary fibrosis and enjoy his family.
  • Pulmonary fibrosis, a fatal lung disease for which there is no cure, devastated the Feldman Family.
  • The mission of the Feldman Family Foundation is to raise awareness and improve the quality of life for families living with pulmonary fibrosis.

Global Idiopathic Pulmonary Fibrosis (IPF) Competitor Market Report 2018: Current Early Stage IPF Pipeline Watch List' and Discontinued/Inactive Candidate List

Retrieved on: 
Wednesday, February 6, 2019
RTT, Medicine, Idiopathic pulmonary fibrosis, IPF, Pulmonary fibrosis, Fibrosis, Clinical medicine, Monoclonal antibodies, Pneumonia, Draft:OliX Pharmaceuticals

The "Competitor Landscape: Idiopathic Pulmonary Fibrosis (IPF)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Competitor Landscape: Idiopathic Pulmonary Fibrosis (IPF)" report has been added to ResearchAndMarkets.com's offering.
  • "Competitor Landscape: Idiopathic Pulmonary Fibrosis (IPF)", briefing contains evaluations of ongoing development activities within the Idiopathic Pulmonary Fibrosis (IPF) disease market, together with analysis of current & potential future product positioning.
  • Pipeline Landscape: An overview of pipeline candidates, containing snapshots of current development status.
  • Approved Product Landscape: An overview of approved candidates, containing snapshots of current development status
    Current Early Stage IPF Pipeline Watch List' and discontinued/inactive candidate list.

Global Idiopathic Pulmonary Fibrosis API Manufacturers, Marketed and Phase III Drugs Landscape Report 2019 - Sales Forecasts to 2021

Retrieved on: 
Wednesday, January 23, 2019
Medicine, Medical terminology, Branches of biology, Health, RTT, Pulmonary fibrosis, Idiopathic pulmonary fibrosis, Fibrosis, Idiopathic disease, Monoclonal antibodies

The "Idiopathic Pulmonary Fibrosis - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Idiopathic Pulmonary Fibrosis - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • Idiopathic Pulmonary Fibrosis - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2019" report provides comprehensive insights about marketed and Phase III products for Idiopathic Pulmonary Fibrosis.
  • The report includes information of marketed products including their product description, patent details, forecasted sales till 2021 & API manufacturer details by country.
  • Coverage of API manufacturers for Idiopathic Pulmonary Fibrosis marketed products spanning across United States, Europe, China and India.